Huber Martin H. Jr. 4

What Happened Martin H. Huber, a director of Syndax Pharmaceuticals, was granted 24,000 restricted stock units (RSUs) on February 4, 2026. The Form 4 reports the acquisition as 24,000 shares at $0.00 (no cash paid by the reporting person). This is an award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-04; transaction type: Award/Grant (code A) of 24,000 RSUs at $0.00 per unit.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — RSUs vest one year from the grant date; underlying shares will not be delivered and cannot be transferred or sold until the earlier of separation from service, death, disability, or a change in control.
• Filing timeliness: No late-filing indicator shown in the provided data.

Context RSU awards to directors are a common form of compensation and do not represent an immediate market purchase or sale. Because these units vest in one year and are restricted until vesting (or certain events), they do not provide immediate liquidity or indicate an immediate change in the director's tradable holdings.